In the E.U., TheraSphere® is used in the treatment of hepatic neoplasia.1

In the U.S., TheraSphere® is indicated for radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment.2

In Canada, TheraSphere® may be used in the treatment of hepatic neoplasia in patients who have appropriately positioned arterial catheters.3